Loading
The first phase 3 trial in metastatic nasopharyngeal cancer found gemcitabine with cisplatin held the disease back for longer than the older fluorouracil-cisplatin combination, and it became the chemotherapy backbone to which immunotherapy was later added.
Chinese multicentre open-label randomised phase 3 trial of 362 patients with recurrent or metastatic nasopharyngeal carcinoma assigned to gemcitabine plus cisplatin or fluorouracil plus cisplatin for up to six cycles.
Median progression-free survival was 7.0 months with gemcitabine-cisplatin against 5.6 months (hazard ratio 0.55), with a higher response rate and a later overall survival advantage; toxicity profiles differed (myelosuppression versus mucositis).
Gemcitabine and cisplatin is the first-line chemotherapy for recurrent or metastatic nasopharyngeal carcinoma and the backbone of the toripalimab, camrelizumab and tislelizumab combinations.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares Fluorouracil (5-FU), Cisplatin.
Shares The Lancet, Cisplatin.
Shares Gemcitabine + cisplatin, The Lancet.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin, Cisplatin.